Apar Kishor Ganti, MD

Articles by Apar Kishor Ganti, MD

This trial combines pembrolizumab and trabedersen to enhance treatment for advanced NSCLC, targeting TGF-β2 for improved patient outcomes.

Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed PD-L1–Positive Metastatic NSCLC

ByOmar K. Abughanimeh, MBBS,Anthony E. Maida III, PhD, MA, MBA,Sanjive Qazi, PhD,Kate-Lynn Muir, DO,Bhavina Sharma MD,Lynette Smith, PhD,Apar Kishor Ganti, MD

October 30th 2025

Clinical Trial Eligibility and Outcomes in Patients With Metastatic NSCLC Treated Outside of Clinical Trials

ByClayton K. Oakley, DO, MS, MA,Amulya Yellala, MD,Sunil Tulpule, MD,Robin High, MA,Apar Kishor Ganti, MD,Alissa S. Marr, MD

December 5th 2024

These data support less restrictive clinical trial eligibility criteria for those with metastatic NSCLC. This is especially true regarding both targeted therapy and immunotherapy treatment regimens.

Factors Associated With Treatment Refusal and Impact of Treatment Refusal on Survival of Patients With Small Cell Lung Cancer

ByPoppy Elvira Deviany, MPH,Apar Kishor Ganti, MD,K.M. Monirul Islam, MD, PhD

March 16th 2021

Original research published in the journal ONCOLOGY® explored the impacts of treatment refusal in patients with small cell lung cancer.

Apar Kishor Ganti, MD

Articles by Apar Kishor Ganti, MD

Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed PD-L1–Positive Metastatic NSCLC

Clinical Trial Eligibility and Outcomes in Patients With Metastatic NSCLC Treated Outside of Clinical Trials

Factors Associated With Treatment Refusal and Impact of Treatment Refusal on Survival of Patients With Small Cell Lung Cancer

Latest Updated Articles

Trending on CancerNetwork

Obesity and Cancer Risk: The Evolving Role of GLP-1s in Oncology

FDA Approves Afami-cel in Metastatic Synovial Sarcoma

EC Approves Encorafenib/Cetuximab/FOLFOX in 1L BRAF V600E–Mutant mCRC

Binimetinib Tablets Receive Tentative FDA Approval in Melanoma/NSCLC

The Moonlight Shift: Dr Joshua Richter on Myeloma, Myths, and the C-Word